Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy.

Moorin, Rachael E

Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy. [electronic resource] - Nuclear medicine communications Apr 2007 - 261-6 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

0143-3636

10.1097/MNM.0b013e328014a11e doi


Animals
Body Burden
Chelating Agents--administration & dosage
Drug Evaluation, Preclinical
Kidney--metabolism
Kidney Diseases--etiology
Male
Metabolic Clearance Rate--drug effects
Neuroectodermal Tumors--metabolism
Octreotide--administration & dosage
Organ Specificity
Peptides--administration & dosage
Radiation Dosage
Radiation Injuries--etiology
Radiation-Protective Agents--administration & dosage
Radiopharmaceuticals--administration & dosage
Rats
Rats, Wistar
Succimer--administration & dosage
Treatment Outcome